Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
This article was originally published in Pharmaceutical Approvals Monthly
Bristol/Gilead joint venture targets 2005 filing for fixed-dose HIV combo. A new brand name for the fixed-dose combination of Bristol’s Sustiva and Gilead’s Truvada is expected. Firms will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products”
You may also be interested in...
Bristol-Myers Squibb and Gilead plan to submit an NDA in the second quarter for a fixed-dose combination of Bristol’s Sustiva (efavirenz) and Gilead’s Truvada (emtricitabine/tenofovir disoproxil).
Gilead Sciences' combination antiretroviral therapy Truvada (emtricitabine/tenofovir) achieved a market-leading 18.7% of total prescriptions in the nucleoside reverse transcriptase inhibitor class during the third quarter, according to Gilead
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011